Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-990-5740
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.97 million
Profitability
Miscellaneous
Employees124
Next Earnings Date3/27/2019 (Estimated)
OptionableOptionable
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings data on Monday, November, 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company earned $11.14 million during the quarter, compared to analysts' expectations of $11.12 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
3 equities research analysts have issued 1 year price objectives for Alimera Sciences' shares. Their forecasts range from $2.75 to $3.00. On average, they anticipate Alimera Sciences' stock price to reach $2.8333 in the next year. This suggests a possible upside of 159.9% from the stock's current price. View Analyst Price Targets for Alimera Sciences.
What is the consensus analysts' recommendation for Alimera Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $190M. This includes a discounted cash flow based enterprise value of the firm at $261M, excluding $40M debt and $30M preferred stock. The DCF analysis utilizes a 15% discount rate and a 2% terminal growth rate." (3/7/2019)
- 2. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (2/21/2019)
Has Alimera Sciences been receiving favorable news coverage?
News coverage about ALIM stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alimera Sciences earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Aduro BioTech (ADRO), Merus (MRUS), Constellation Pharmaceuticals (CNST), Immune Design (IMDZ), Lannett (LCI), Savara (SVRA), BIOFRONTERA AG/ADR (BFRA), TapImmune (MRKR), Xeris Pharmaceuticals (XERS), Strongbridge Biopharma (SBBP), Evelo Biosciences (EVLO), Seres Therapeutics (MCRB), Aclaris Therapeutics (ACRS), Kala Pharmaceuticals (KALA) and Affimed (AFMD).
What other stocks do shareholders of Alimera Sciences own?
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
- Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
- Dr. Kenneth Green, Sr. VP, Chief Scientific Officer and Global Head of R&D (Age 61)
- Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
- Mr. J. Philip Jones, Chief Financial Officer (Age 55)
Who are Alimera Sciences' major shareholders?
Alimera Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (9.34%), B. Riley Financial Inc. (0.61%), Knott David M (0.55%), Royce & Associates LP (0.46%) and B. Riley Wealth Management Inc. (0.15%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.
Which institutional investors are selling Alimera Sciences stock?
Which institutional investors are buying Alimera Sciences stock?
ALIM stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Knott David M and B. Riley Wealth Management Inc.. Company insiders that have bought Alimera Sciences stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $1.09.
How big of a company is Alimera Sciences?
Alimera Sciences has a market capitalization of $77.36 million and generates $46.97 million in revenue each year. The biopharmaceutical company earns $-16,380,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe.
What is Alimera Sciences' official website?
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
